Pharmaceutical Continuous Manufacturing Market Outlook - 2026
The global pharmaceutical continuous manufacturing market was valued at $393 million in 2018, and is projected to reach $855 million by 2026, registering a CAGR of 10.2% from 2019 to 2026.
Continuous manufacturing is an advanced manufacturing approach with the potential to improve quality and consistency of medications with lower cost. This production line is operated in a continuous flow, with end-to-end integration of manufacturing processes. The pharmaceutical continuous manufacturing market is expected to witness significant growth during the forecast period, due to technological advancements in continuous manufacturing systems and support by the regulatory authorities for adoption of continuous manufacturing systems. However, higher cost of pharmaceutical continuous manufacturing systems impedes the pharmaceutical continuous manufacturing market growth. On the contrary, pharmaceutical manufacturing systems reduce fluctuation in the production, improve yields, lower cost of operation & equipment, which are anticipated to offer remunerative opportunities for market expansion. Recently, in 2019, Caperion launched a next-generation of high accuracy vibratory feeding technology with higher accuracy and quicker product changeover.
Global Pharmaceutical Continuous Manufacturing Market Segmentation
The global pharmaceutical continuous manufacturing market is segmented into product, application, end user, and region. Depending on product, the market is classified into integrated continuous systems, semicontinuous systems, and control & software. The applications covered in the study covered include final drug product manufacturing and API manufacturing. On the basis of end user, the market is categorized into pharmaceutical companies, contract manufacturing organizations, and others. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Segment review
Depending on product, the integrated continuous systems segment hold the largest pharmaceutical continuous manufacturing market share in 2018, and is anticipated to exhibit significant growth during the forecast period. This is attributed to increase in adoption of integrated continuous manufacturing (ICM) process and availability of ICM systems.
By Product Type
Integrated Continuous Systems is projected as one of the most lucrative segment.
Depending on application, the final drug product manufacturing segment presently acts as the major revenue generator, and is anticipated to experience significant growth during the forecast period. Rise in number of pharmaceutical companies, technological advancements in continuous manufacturing systems, and rise in demand for pharmaceutical drugs are key drivers of this market. However, API is anticipated to exhibit fastest growth during the forecast period, due to increase in number of R&D activities to develop API with continuous manufacturing system. Furthermore, increase in number of approved drugs produced by continuous processes drives the market growth. For instance, Orkambi by Vertex, Prezista by Janssen, Verzenio by Eli Lilly and Company, and Symdeko by Vertex are produced by continuous manufacturing processes.
By Application
Final Drug Product Manufacturing holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Snapshot of Asia-Pacific pharmaceutical continuous manufacturing market
Asia-Pacific presents lucrative opportunities for the key players operating in the pharmaceutical continuous manufacturing market, due to increase in awareness about advanced pharmaceutical continuous manufacturing systems, rise number of pharmaceutical companies, and increase in demand for continuous manufacturing systems. However, higher cost of pharmaceutical continuous manufacturing systems may hamper the market growth in Asia-Pacific.
By Geography
Asia-Pacific region would exhibit the highest CAGR of 11.5% during 2019-2026.
The key players profiled in this report include Bosch Packaging Technology, Coperion GmbH, GEA Group AG, Gebrüder Lödige Maschinenbau GmbH, Glatt GmbH, Hosokawa Micron Corporation, Korsch AG, L.B. Bohle Maschinen + Verfahren GmbH, Munson Machinery Company, Inc., and Thermo Fisher Scientific Inc.
Key Benefits for Pharmaceutical Continuous Manufacturing Market:
- The study provides an in-depth analysis of the pharmaceutical continuous manufacturing market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It provides pharmaceutical continuous manufacturing market analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of key players are thoroughly analyzed to understand the competitive outlook and global pharmaceutical continuous manufacturing market growth.
Pharmaceutical Continuous Manufacturing Market Report Highlights
| Aspects | Details |
 By PRODUCT |
|
 By APPLICATION |
|
 By END USER |
|
 By Region |
|
 Key Market Players | GEBRÜDER LÖDIGE MASCHINENBAU GMBH, GEA Group AG, Munson Machinery Company, Inc, Hosokawa Micron Corporation, KORSCH AG, Glatt GmbH, Coperion GmbH, Robert Bosch Packaging Technology GmbH, Thermo Fisher Scientific, Inc, L.B. Bohle Maschinen + Verfahren GmbH |
Analyst Review
Continuous manufacturing is advanced manufacturing approach to provide pharmaceutical products with improved yield within shorter time period.
Development of the pharmaceutical industry and improvement in productivity of pharmaceuticals with reduced costs are key factors that driving the growth of Pharmaceutical Continuous Manufacturing Market. In addition, initiatives taken by the U.S. FDA for promoting the use of pharmaceutical manufacturing systems for modernizing pharmaceutical manufacturing process and advantage over the batch manufacturing are the major factors that boost the growth of the global market. However, high cost of pharmaceutical continuous manufacturing is a key factor, which hinder the market growth.
North America is expected to remain dominant during the forecast period due to higher adoption of pharmaceutical continuous manufacturing systems, large presence of pharmaceutical companies, availability of advanced pharmaceutical continuous manufacturing systems, and supportive government policies for adoption of continuous manufacturing. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to increase in adoption of pharmaceutical continuous manufacturing systems along with rise in presence of key pharmaceutical companies in Asia-Pacific.
Loading Table Of Content...
